• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

New Johns Hopkins’ Study Shows Psilocybin Promotes Mental Health Improvements

Microdose NewsDesk by Microdose NewsDesk
September 19, 2023
in Science
Reading Time: 1 min read
A A
New Johns Hopkins’ Study Shows Psilocybin Promotes Mental Health Improvements

A new study published by researchers from the Johns Hopkins’ Center for Psychedelic and Consciousness Research shows that psilocybin produces lasting improvements in mental health symptoms and general wellbeing.

“Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing” is the largest survey of naturalistic psilocybin use to date, and the results support other data on psilocybin’s effectiveness.

  • A sample of 2,833 respondents completed assessments 2 weeks before psilocybin use; 1,182 completed the 2–4 week post-use survey; and 657 completed the final follow-up survey 2–3 months after psilocybin use.
  • Participants primarily used dried psilocybin mushrooms (mean dose = 3.1 grams) for “self-exploration” purposes.
  • Order Genuine Lasix Now
  • data collected before and after the psilocybin experience on average showed persisting reductions in anxiety, depression, and alcohol misuse, increased cognitive flexibility, emotion regulation, spiritual well-being, and extraversion, and reduced neuroticism and burnout after psilocybin use.

 

We’ll leave it to Johns Hopkins to give us more context on the study. See their thread below.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Respondents planning to use psilocybin for self-exploration participated in a longitudinal survey study, measured at baseline (n=2833), 1-3 days post psilocybin (n=1551), 2-4wks post (n=1182), and 2-3mo post (n=657). Respondents were mostly white and college educated. 2/7

— Johns Hopkins Psychedelic Research Center (@JHPsychedelics) September 19, 2023

On average, participants showed significant reductions in depressed mood, anxiety, and personal burnout, and significant increases in cognitive flexibility and spiritual well-being that were still detectable up to 2 months after the experience. 3/7 pic.twitter.com/0astApfHiA

— Johns Hopkins Psychedelic Research Center (@JHPsychedelics) September 19, 2023

These experiences were rated as less meaningful than those we tend to see in the lab. 5/7 pic.twitter.com/PgKiJfIR5C

— Johns Hopkins Psychedelic Research Center (@JHPsychedelics) September 19, 2023

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: Johns Hopkinspsilocybin
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Numinus Closes Bioscience Lab and Consolidates Clinics

Numinus Closes Bioscience Lab and Consolidates Clinics

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.